Prana continues Alzheimer's drug trial in Australia

07/4/2013 | RTT News · Bloomberg Businessweek

An Australian hospital has cleared Prana Biotechnology's request to conduct a 12-month extension study of PBT2, the company's Alzheimer's disease drug candidate. PET imaging will be used to examine changes in the brains of Alzheimer's patients who have received PBT2 treatment for 12 months as part of the company's IMAGINE trial.

View Full Article in:

RTT News · Bloomberg Businessweek

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Operating Officer
Health Plan of San Joaquin
French Camp , CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Children's Health Plan
Houston, TX
Chief Information Officer
Meridian Health Plan
Detroit, MI
NTA Life
Addison, TX
Vice President - Government Products
Health Alliance Plan
Detroit, MI